TLR-9 is located in endosomal compartments of APCs, affording nanoparticles to be readily trafficked into endosomes following cellular uptake, where they can be degraded to release encapsulated tumor antigens for processing, presentation on MHC molecules, and subsequent activation of tumor antigen-specific T cells [18]. The gene discussed is HLA-C; the disease is neoplasm.